[Intravesical chemoprophylaxis with beta-interferon in superficial carcinoma of the bladder].
24 patients with recurrent (group 1) or primary (group 2) bladder cancer (ta/t1 G2) were given 50.000.000 U.I. of beta interferon intravesically after TUR of the neoplasm. In group 1 recurrence rate (rr) was 100% in the period before INF and 83% after INF treatment (follow-up 15-24 months, median 19.8) (p = ns). In group 2 rr was 25% in a 24 months, median 19.8) (p = ns). In group 2 rr was 25% in a 24 months follow-up period; if compared to the rr of a historical control group treated by only a TUR (38.2%) there was a statistically significant difference (p less than 0.01). Tolerability of the drug was excellent.
Migliari
R
R
Clinica Urologica, Università di Cagliari.
el-Demiry
M I
MI
Muscas
G
G
Dore
A
A
Migliari
M
M
Usai
E
E
D000283:Administration, Intravesical; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control*
D007370:Interferon Type I
Chemioprofilassi endovescicale con beta-interferone nel carcinoma superficiale della vescica.